Literature DB >> 3995108

Cholinesterase activity in plasma, erythrocytes, and cerebrospinal fluid of patients with dementia of the Alzheimer type.

J K Marquis, L Volicer, K A Mark, L K Direnfeld, M Freedman.   

Abstract

Cholinesterases, including pseudocholinesterase (BChE) of human plasma and acetylcholinesterase (AChE) of erythrocytes and cerebrospinal fluid (CSF), have been considered as possible markers in dementia of the Alzheimer type (DAT). Reported data, however, are widely varied, and no significant pattern emerges when total enzyme activity is assayed. In the present studies, we have reexamined the relationship of ChE activities in DAT and control patients. ChE activity was measured in plasma, erythrocytes, and CSF from DAT patients and compared with normal controls as well as with samples from patients with a diagnosis other than DAT. Early age onset (presenile) and late age onset (senile) DAT were also compared. No significant differences in total enzyme activity were found in any of the comparisons. Calculations of AChE/BChE ratios in CSF also provided no significant indication of any changes in ChE activities in DAT. It is suggested that measurements of total AChE or BChE activity in these biological materials do not provide a useful index of alterations in central cholinergic function in patients with DAT.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3995108     DOI: 10.1016/0006-3223(85)90095-2

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  7 in total

1.  Cholinesterases in the cerebrospinal fluid, plasma, and erythrocytes of patients with Alzheimer's disease.

Authors:  J Sirviö; R Kutvonen; H Soininen; P Hartikainen; P J Riekkinen
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

2.  Serum and CSF cholinesterase activity in various kinds of dementia.

Authors:  A K Szilágyi; A Németh; E Martini; B Lendvai; V Venter
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1987

3.  Biological markers in cerebrospinal fluid for axonal impairment in multiple sclerosis: acetylcholinesterase activity cannot be considered a useful biomarker.

Authors:  T Antonelli; M C Tomasini; M Castellazzi; P Sola; C Tamborino; D Ferraro; L Ferraro; E Granieri
Journal:  Neurol Sci       Date:  2012-12-18       Impact factor: 3.307

4.  Acetylcholinesterase and butyrylcholinesterase activities in cerebrospinal fluid from different levels of the neuraxis of patients with dementia of the Alzheimer type.

Authors:  M E Appleyard; B McDonald
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-11       Impact factor: 10.154

5.  Monoclonal antibodies to human brain acetylcholinesterase: properties and applications.

Authors:  Z Rakonczay; S Brimijoin
Journal:  Cell Mol Neurobiol       Date:  1988-03       Impact factor: 5.046

6.  Evidence of upregulation of the cholinergic anti-inflammatory pathway in late-life depression.

Authors:  Nunzio Pomara; Davide Bruno; Chelsea Reichert Plaska; Anilkumar Pillai; Jaime Ramos-Cejudo; Ricardo Osorio; Bruno P Imbimbo; Amanda Heslegrave; Henrik Zetterberg; Kaj Blennow
Journal:  J Affect Disord       Date:  2021-03-09       Impact factor: 4.839

7.  Altered levels of acetylcholinesterase in Alzheimer plasma.

Authors:  María-Salud García-Ayllón; Iolanda Riba-Llena; Carol Serra-Basante; Jordi Alom; Rathnam Boopathy; Javier Sáez-Valero
Journal:  PLoS One       Date:  2010-01-14       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.